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was £4,142 compared to £3,762 on PE. Overall tumour
response was 40.6% and 21.9% respectively and progres-
sion-free life years 0.575 and 0.358. Thus, the incremen-
tal cost-per-tumour-response of GC was £2,032 and the
incremental cost-per-progression-free-life-year £1,751. In
the final setting, the cost of GC was £5,084 and of MVP
£4,004. Overall tumour response was 54.0% and 36.7%
and one year survival 36% and 17% respectively. The in-
cremental cost-per-tumour-response of GC was £6,240
and the incremental cost-per-survivor-at-one-year was
£5,681. In extreme changes to underlying variables the
above ratios vary from dominance to a maximum of
£14,000. CONCLUSIONS: These results demonstrate
that Gemzar/cisplatin represents a relatively cost-effective
treatment for NSCLC with ratios comparable of below
those of therapies currently in use within the NHS.
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THE VALUE OF COMPLIANCE: EVIDENCE FROM 
TWO PATIENT COHORTS
McGuigan KA, Sokol M, Yao J, Haynes J, Qian Q, Boscarino J, 
Epstein R
Merck-Medco Managed Care, LLC, Franklin Lakes, NJ, USA
OBJECTIVES: To identify the association between com-
pliance and the direct costs of care for two different clini-
cal patient cohorts. METHODS: Using administrative
claims data from Medstat MarketScan (tm) we assessed
the association between prescription drug compliance
and direct costs of care for two patient groups: a cohort
of non-Medicare patients diagnosed as diabetics (N 
9960) and second cohort of non-Medicare patients diag-
nosed with congestive heart failure (CHF)(N  935).
Since patients who are more compliant tend to be older
and have a greater number of comorbidities, and our goal
was to isolate the association between compliance and
medical care costs, we statistically controlled for differ-
ences in potential confounding variables using OLS re-
gression. Covariates included age, gender, comorbidity
indices (Chronic Disease Score and Charlson-Deyo), and
ICD-9-based severity of illness indicators. Compliance
was defined by calculating % days supply over a period
of one year. Compliance was then converted to 7 ordinal
categories in the regression model in order to identify
dose-response associations or threshold/inflection points.
RESULTS: Among diabetics, those who did not use any
prescription medication showed the lowest total costs of
care. However, among those patients who needed pre-
scription medication to manage their illness, increased
prescription drug costs among the most compliant are
more than offset by decreases in medical care costs, for
an estimated return on investment (ROI) of more than
two-fold. A similar, but stronger, pattern was found
among patients with CHF where the estimated ROI was
three-fold or greater. CONCLUSIONS: For some medi-
cal conditions, the additional costs associated with in-
creased compliance may be offset by lower medical costs,
resulting in an ROI greater than one.
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INDIRECT COMPARISONS OF DRUGS USING 
META-ANALYSIS: VALIDATION OF RESULTS
Ross SD1, Klawansky S1, Allen IE2
1MetaWorks, Medford, MA, USA; 2Babson College, Wellesley, 
MA, USA
OBJECTIVES: Health care decision-makers need more
head-to-head drug comparison trials. Industry rarely
sponsors such studies, preferring placebo comparators.
We present an example of using meta-analysis for an in-
direct comparison of 2 drugs, with the results subse-
quently validated in a direct comparison trial. METH-
ODS: The drugs for comparison were abciximab and
tirofiban, both GPIIb/IIIa inhibitors used in patients with
acute coronary syndromes undergoing percutaneous cor-
onary interventions (PCI). A class effect has been as-
sumed for these agents, although they differ in molecular
structure and duration of action. We identified all pla-
cebo-controlled trials of each drug in PCI patients, and
meta-analysed the odds ratios (OR) for death or MI
(D/MI) at 30 days for each set of studies. These ORs were
then compared using a general linear model. RESULTS:
For D/MI at 30 days, the results of the meta-analysis of
the 6 abciximab studies [OR  0.52 (0.43, 0.63)] ap-
peared superior to the results of the 3 tirofiban studies
[OR  0.73 (0.55, 0.96)], although the differences did
not reach significance. In the model, a non-significant (p 
0.10) abciximab advantage was observed. The ratio of
the ORs of tirofiban/placebo and abciximab/placebo
meta-analyses was 1.4, suggesting a higher risk of D/MI
at 30 days for tirofiban relative to abciximab. After com-
pletion of these analyses, the results of a randomized
comparison trial of tirofiban vs. abciximab in PCI pa-
tients were announced (for D/MI at 30days OR  1.26,
p  0.04). The results demonstrated an advantage for ab-
ciximab, in keeping with our meta-analysis result. The
magnitude of the efficacy difference was similar to that
we had predicted. CONCLUSIONS: This is the first time
an indirect comparison of drugs using meta-analytic tech-
niques has been validated with a contemporaneous RCT.
This method should be used to predict results of direct
comparisons of drugs anytime such a trial is contem-
plated.
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DO SHORT-ACTING OPIATES IN OFF-PUMP 
BYPASS SURGERY REDUCE LENGTH OF STAY 
OR TOTAL HOSPITAL COSTS?
Reddy P1, Feret B2, Kulicki L2, Jordan S2, Donahue S2, Quercia R2
1University of Connecticut, Storrs, CT, USA; 2Hartford Hospital, 
Hartford, CT, USA
OBJECTIVES: The cost of remifentanil, a short-acting
opiate, is approximately 10 times higher than fentanyl, a
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longer-acting opiate. Short-acting opiates, however, have
the potential to reduce time to extubation (TTE) and
may, therefore, decrease length of stay (LOS) and hospi-
tal costs. Remifentanil was added to our institution’s
formulary for use during off-pump bypass surgery. The
objective of this analysis was to compare TTE, LOS
and total hospital costs between patients who received
remifentanil and fentanyl during off-pump bypass sur-
gery. METHODS: The study was prospective and obser-
vational in design. Consecutive patients who underwent
off-pump cardiac bypass surgery and received either
remifentanil or fentanyl from September 1998 to August
1999 were included. Patient charges were converted to
costs using cost-to-charge ratios. The percent of patients
extubated in the operating room (OR), LOS and hospital
costs were compared between the groups. RESULTS:
Baseline demographics, including age, female patients,
co-morbidities and intraoperative variables were similar
between the remifentanil (n  39) and fentanyl (n  20)
groups. Patients given remifentanil during surgery were
significantly more likely to be extubated in the OR than
patients given fentanyl (64% vs. 15%; p  0.001). The
mean LOS was similar in both groups (7.3  3.1d vs. 8.3 
2.7d; p  0.27). Patients who received remifentanil in-
curred lower ward ($3,973  1,719 vs. $4,808  1,794;
p  0.09), recovery room ($31  40 vs. $65  33; p 
0.002) and pulmonary function testing costs ($0  0 vs.
$34  103; p  0.045) than patients who received fenta-
nyl. Anesthesia costs were higher among patients who re-
ceived remifentanil ($476  102 vs. $416  130; p 
0.06). Medical and surgical supplies, OR, ICU, cardiac
catheterization, laboratory, respiratory therapy, phar-
macy, radiology and transfusion costs were similar be-
tween the 2 groups (p  0.05). The total cost was
$15,272  5,556 and $15,616  4,169 in the remifenta-
nil and fentanyl groups, respectively (p  0.81). CON-
CLUSION: Remifentanil, when used in off-pump bypass
surgery, increases the likelihood of extubation in the OR.
However, LOS and total hospital costs remain un-
changed.
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USING UK OBSERVATIONAL DATA TO 
IDENTIFY POSSIBILITIES FOR THE
COST-EFFECTIVE IMPROVEMENT OF THE 
TREATMENT OF ATRIAL FIBRILLATION
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BACKGROUND: Atrial Fibrillation (AF) is the most fre-
quent type of arrhythmia. Termination of acute AF is
generally undertaken in a hospital setting. Available
drugs for termination of acute AF have severe side effects
and complicated dose regimens. There is a need for new
drugs with a high conversion rate, favourable safety pro-
file and easier dosing. OBJECTIVES: To describe the
characteristics and hospital treatment patterns of patients
with AF. To investigate the requirements for an improved
cost-effective anti-arrhythmic therapy. METHODS: A
database was used containing aggregated and anonymised
diagnostic information, hospital experience (e.g., length
of stay), and demographic data for over 80 million inpa-
tient episodes in the UK over ten years. The database
contains 28,524 hospital admissions of patients (65 and
over) with a diagnosis of AF during 1999/2000. 53.3%
are female, with mean length of stay (LOS) 6.1 days;
46.7% are male with LOS 4.3 days. Controlling for age,
the gender LOS difference is significant (p  0.01). RE-
SULTS: Comorbid Conditions. 17.5% of AF patients
also had a diagnosis of chronic ischaemic heart disease
(IHD), a further 7.5% had myocardial ischaemia, and
19.5%, congestive heart failure. Furthermore, 24.2% of
CHF patients and 16.9% of all angina patients also had
clinically significant AF. Cardioversion. Cardioversion
(defibrillation) is used when pharmacological therapy
fails to terminate acute AF. However, significant num-
bers (35%) of cardioversion procedures were undertaken
on an elective day case basis. We are currently investigat-
ing and will report on the resource consequences in acute
AF. CONCLUSIONS: There is a clear unmet medical
need for improved anti-arrhythmic drugs. Using the
dataset, we identify two potentially cost-effective possi-
bilities for improved anti-arrhythmic treatment: an agent
which can simultaneously demonstrate effectiveness in
associated cardiovascular conditions such as IHD or
CHF; or an agent reducing the need for cardioversion in
acute AF.
CV5
THE COST-EFFECTIVENESS OF LIFETIME 
FACTOR VIII PROPHYLAXIS IN THE 
TREATMENT OF SEVERE HEMOPHILIA A
Charles RA1, Hay J2
1University of Southern California, School of Pharmacy, Los 
Angeles, CA, USA; 2University of Southern California, Los 
Angeles, CA, USA
Prophylactic infusion of factor VIII has been shown to
markedly reduce arthropathy in patients with severe he-
mophilia A. OBJECTIVE: The purpose of this model is
to investigate the cost-effectiveness of prophylactic infu-
sion of factor VIII relative to on-demand infusion therapy
in patients with severe hemophilia A. METHODS: Two
hypothetical cohorts were modeled; one cohort receiving
prophylactic and the other on-demand infusions. Factor
VIII infusion therapy begins at age 1 and continues un-
changed over a patient’s lifetime. A recursive Markov
model is used to estimate the expected costs and QALYs
associated with each cohort. Costs and QALYs are calcu-
lated using backward induction in 5-year intervals incor-
porating the DEALE method. Data inputs are estimated
from published literature. The analysis is completed from
a societal perspective, uses a 3% discount rate, with costs
in year 2000 U.S. dollars, and has a time horizon of 50
years. RESULTS: According to the model, patients re-
